<code id='A257610203'></code><style id='A257610203'></style>
    • <acronym id='A257610203'></acronym>
      <center id='A257610203'><center id='A257610203'><tfoot id='A257610203'></tfoot></center><abbr id='A257610203'><dir id='A257610203'><tfoot id='A257610203'></tfoot><noframes id='A257610203'>

    • <optgroup id='A257610203'><strike id='A257610203'><sup id='A257610203'></sup></strike><code id='A257610203'></code></optgroup>
        1. <b id='A257610203'><label id='A257610203'><select id='A257610203'><dt id='A257610203'><span id='A257610203'></span></dt></select></label></b><u id='A257610203'></u>
          <i id='A257610203'><strike id='A257610203'><tt id='A257610203'><pre id='A257610203'></pre></tt></strike></i>

          Home / fashion / leisure time

          leisure time


          leisure time

          author:hotspot    Page View:9974
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In